Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: p53 is the most frequently mutated tumor-suppressor gene in human cancers. It has been reported that mutations in p53 result not only in the loss of its ability as a tumor suppressor, but also in the gain of novel cancer-related functions that contribute to oncogenesis. The present study evaluated the potential of silencing of mutant p53 by small interfering RNA in the treatment of bladder cancer cells in vitro. Methods: We used the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay to assess cell viability and flow cytometry to detect cell cycle alterations and apoptosis. The related molecular mechanisms were assessed by western blotting. We also used the MTT assay and flow cytometry to investigate if silencing of mutant p53 by knockdown with small interfering (si)RNA would change the sensitivity to cisplatin treatment. Results: Using 5637 and T24 human bladder cancer cell lines characterized by mutations in p53, we found that silencing of the mutant p53 by RNA interference induced evident inhibition of cell proliferation and viability, which was related to the induction of G2 phase cell cycle arrest and apoptosis. Moreover, our study also showed that the p53-targeting siRNA cooperated with cisplatin in the inhibition of bladder cancer cells. Conclusions: These findings suggest that RNA interference targeting mutant p53 may be a promising therapeutic strategy for the treatment of bladder cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 1×
“These stresses trigger the accumulation of p53 protein and activate its transcriptional activity, which prevents cell transformation by inducing cell cycle arrest, senescence, apoptosis, DNA repair, or autophagy [5,6].”
BackgroundCytoplasmic functions of the tumour suppressor p53
Green, D. R., & Kroemer, G. (2009) · Nature · doi:10.1038/nature07986 · Cited by 1,106 · cited 1×
“These stresses trigger the accumulation of p53 protein and activate its transcriptional activity, which prevents cell transformation by inducing cell cycle arrest, senescence, apoptosis, DNA repair, or autophagy [5,6].”
BackgroundCommon markers of proliferation
Whitfield, M. L., George, L. K., Grant, G. D., & Perou, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1802 · Cited by 650 · cited 1×
“In numerous cancer types, mutations in TP53 are strongly associated with high expression levels of the proliferation-associated gene cluster, comprised mainly of the genes that participate in the core processes of the cell cycle [30].”
BackgroundVikhanskaya, F., Lee, M. K., Mazzoletti, M., Broggini, M., & Sabapathy, K. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm099 · Cited by 145 · cited 1×
“Moreover, several p53 mutants were recently shown to repress wild-type p53 target genes, which encode pivotal cell cycle inhibitors (such as p21 and GADD45α (growth arrest and DNA-damageinducible 45α)), leading to alteration of cyclins/CDKs and an increased proliferation rate [31].”
BackgroundDevelopmental abnormalities in transgenic mice expressing a sialic acid-specific 9-O-acetylesterase
Varki, A., Hooshmand, F., Diaz, S., Varki, N. M., & Hedrick, S. M. (1991) · Cell · doi:10.1016/0092-8674(91)90408-q · Cited by 134
Cited by
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
“…in increased apoptosis, indicating that these cells may have become dependent on mutant p53 for their survival (Table 1; Ali et al., 2013; Braicu et al., 2013; Huang et al., 2013; Hui et al., 2006; Lim et al., 2009; Vakifahmetoglu-Norberg et al., 2013; Xie et al., 2013; Zhu et al., 2011, 2013).”
BackgroundTargeting Oncogenic Mutant p53 for Cancer Therapy
Parrales, A., & Iwakuma, T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00288 · Cited by 337
Yun, J., Lee, S.-H., Kim, S.-Y., Jeong, S.-Y., Kim, J.-H., Pyo, K.-H., Park, C.-W., Heo, S. G., Yun, M. R., Lim, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0116 · Cited by 297
“Indeed, accumulated studies have revealed that the R280T mutation in TP53 plays crucial roles in the proliferation and survival of cancer cells, and knockdown of the mutant TP53 causes G2-phase arrest and apoptosis in bladder cancer cells (26, 27).”
Background
Metadata
- Authors
- Zhu, H.-B., Yang, K., Xie, Y.-Q., Lin, Y.-W., Mao, Q.-Q., & Xie, L.-P.
- Venue
- World Journal of Surgical Oncology
- Published
- 2013-01-28
- Volume
- 11
- Issue
- 1
- Pages
- 22-22
- ISSN
- 1477-7819 (ISSN-L)
- OpenAlex
- W2124156171
- Cited by
- 64
- References
- 5
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells. https://app.cochat.ai/papers/10.1186/1477-7819-11-22
- The paper
- Zhu, H.-B., Yang, K., Xie, Y.-Q., Lin, Y.-W., Mao, Q.-Q., & Xie, L.-P. (2013). Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells. World Journal of Surgical Oncology. https://doi.org/10.1186/1477-7819-11-22
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.